Industry News
Sigma Life Science to distribute Olink Bioscience’s protein interaction analysis technology
Sigma-Aldrich Corporation has announced that Sigma Life Science, its innovative biological products and services business, has signed an agreement to distribute worldwide Olink Bioscience’s Duolink In Situ products, which present a disruptive method for imaging and measuring protein-protein interactions in unmodified cells. [ + ]
Optibrium and Lhasa collaborate to bring expert toxicity prediction to chemists’ desktops
Optibrium and Lhasa, providers of software for compound design, selection and property prediction, have announced a technology collaboration agreement. [ + ]
Allied receives ISO certification for CardioCel
Allied Healthcare (ASX:AHZ) has received ISO 13485 certification for regenerative therapy CardioCel, bringing it a step closer to European CE Mark approval. [ + ]
Wollongong to host world-leading scientists for symposium
More than 150 leading Australian and international researchers will converge on Wollongong this week to speak about and share insights into groundbreaking materials research as part of the 8th Annual International Electromaterials Science Symposium. [ + ]
UC researching new forms of tumour detection
Researchers at the University of Canterbury are working on new forms of tumour detection in the hope of reducing the annual cancer toll. [ + ]
Unlocking the genetic secrets of avian hairstyles
Sir Walter Murdoch Adjunct Professor Thomas Gilbert is part of an international team that has helped decode the genetic blueprint of the common pigeon (Rock Pigeon/Feral Pigeon) in a breakthrough that sheds light into the minute building blocks of evolution. [ + ]
Phosphagenics solves oxycodone patch design problems and plans for new trial
Phosphagenics (ASX:POH) has solved the crystallisation problems with its oxycodone patch and is aiming to re-enter the clinic by the end of this quarter. [ + ]
Bioniche details plans for Urocidin
In a letter to shareholders, Bioniche’s (ASX:BNC) CEO has laid out some plans for the future of bladder cancer treatment Urocidin following its split with former commercialisation partner Endo Pharmaceuticals. [ + ]
BioDiem testing BDM-I in schistosomiasis
BioDiem (ASX:BDM) and the QIMR are moving to proof-of-concept testing of BioDiem’s antimicrobial in the parasitic worms that cause the major tropical disease schistosomiasis. [ + ]
Cellmid options cancer diagnostics tech
Cellmid (ASX:CDY) has secured an option agreement with Japan’s Fujikura covering its midkine cancer diagnostics technology in latex-based tests. [ + ]
KAG announces alliance with maxon motor
Kählig Antriebstechnik GmbH has appointed maxon motor Australia Pty Ltd as its distributor for Australia and New Zealand. [ + ]
Australian innovation gets a head start with Baxter Commercialisation
Baxter Innovation Hub has launched its new commercialisation service, Baxter Commercialisation, comprising an experienced team of industry specialists dedicated to assisting Australian inventors and entrepreneurs in expanding their business and selling their ideas to the world. [ + ]
Mesoblast up following patents in US and China
Mesoblast (ASX:MSB) has made gains on the ASX following an announcement it has secured further patents covering its technology in the US and China. [ + ]
New insight into the catch-22 of obesity and dieting
Australian researchers have unravelled a longstanding mystery of obesity: why is it sometimes counterproductive for obese people to diet? [ + ]
Australia’s first ever snapshot of science engagement
The first national audit of its kind ever to be held in Australia recorded information about 411 different activities that aim to engage ordinary people with science. [ + ]
